Bipar Sciences

bipar sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called parp inhibitors, designed to target multiple cancer types, including therapy-resistant and difficult-to-treat cancers. bipar sciences' lead product candidate, iniparib, the united states adopted name (usan) for the investigational parp1 inhibitor, bsi-201, targets parp, or poly (adp-ribose) polymerase, a key enzyme involved in dna repair and cell proliferation. iniparib significantly enhances the anti-tumor effects of chemotherapy and has shown promising safety and efficacy results in patients with solid tumors. iniparib is being evaluated in multiple phase 2 and phase 3 clinical trials in advanced solid tumors, including triple-negative breast cancer. the company also has two additional compounds in pre-clinical development: bsi-401, a follow-on parp inhibitor candidate being investigated as an oral therapy for pancreatic cancer, and bsi-302, a novel anti-t